Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTOGet Free Report) (TSE:APS) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 2,090,000 shares, a growth of 1,012.9% from the December 31st total of 187,800 shares. Based on an average trading volume of 6,360,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 3.7% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its position in Aptose Biosciences Inc. (NASDAQ:APTOFree Report) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is owned by institutional investors.

Aptose Biosciences Price Performance

NASDAQ:APTO opened at $0.19 on Wednesday. The company has a market cap of $11.54 million, a P/E ratio of -0.06 and a beta of 0.87. The firm’s fifty day moving average price is $0.21 and its two-hundred day moving average price is $0.36. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.20.

Analyst Ratings Changes

Several research analysts have recently weighed in on APTO shares. StockNews.com initiated coverage on shares of Aptose Biosciences in a research note on Friday, January 24th. They set a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a research report on Friday, January 10th.

Check Out Our Latest Report on APTO

About Aptose Biosciences

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.